Focused On-demand Library for Lysine-specific demethylase 5D

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Histocompatibility Y antigen; Histone demethylase JARID1D; Jumonji/ARID domain-containing protein 1D; Protein SmcY; [histone H3]-trimethyl-L-lysine(4) demethylase 5D

Alternative UPACC:

Q9BY66; A2RU19; A6H8V7; B7ZLX1; Q92509; Q92809; Q9HCU1


Lysine-specific demethylase 5D, known as Histone demethylase JARID1D, plays a pivotal role in histone code by specifically demethylating 'Lys-4' of histone H3. It is crucial in processes such as spermatogenesis and transcriptional repression of metastasis-associated genes, working alongside ZMYND8 to suppress prostate cancer cell invasion and regulate androgen receptor transcriptional activity.

Therapeutic significance:

Understanding the role of Lysine-specific demethylase 5D could open doors to potential therapeutic strategies, particularly in the context of cancer treatment and reproductive health.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.